Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib vs Ixazomib-Lenalidomide Maintenance in MM
NCT03733691Phase 2Terminated
- Sponsor
- ONCOtherapeutics
- Start
- Mar 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Started Mar 2019; status: terminated.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03733691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733691.